LVPEI, BostonSight to study mental health effects of PROSE, Scleral lenses
BostonSight and Hyderabad-based LVPEI have launched a prospective clinical trial to study the mental health effects of PROSE and scleral lenses. The multi-site study will assess patient outcomes and explore whether specialty lenses can improve quality of life and support earlier intervention.
Hyderabad: BostonSight and Hyderabad-based LV Prasad Eye Institute (LVPEI) on Monday announced the launch of a prospective clinical trial to evaluate the effect of PROSE and SCLERAL lenses on mental health.
The collaboration marks a step in BostonSight’s ongoing research into the efficacy of the lenses in improving quality of life of users, going beyond its previous research on impact on cornea and ocular surface.
The multi-site study will involve the lens users referred to LVPEI and will focus on evaluating mental health outcomes of patients who have had BostonSight PROSE and SCLERAL lenses fitted, a statement from LVPEI on Monday said.
The primary objective of the study is to identify a direct correlation between quantifiable mental health outcomes and specialty lens treatment. The study also aims to raise awareness of mental health challenges associated with ocular surface disease and promote early interventions with PROSE to improve or avoid associated mental health conditions.
“We are excited to move forward with this important study to evaluate quantifiable mental health outcomes associated with these specialty lenses,” said Dr Prashant Garg, Executive Chair, LVPEI.
“With this study, we hope to objectively measure this effect, which could further support earlier interventions in a patient’s eye care journey, with PROSE and other specialty lenses,” said Dr Daniel Brocks, Chief Medical Officer – BostonSight
